Development
Ocular Therapeutix, Inc.
OCUL
$8.18
-$0.15-1.80%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.16% | 26.04% | 23.81% | 1.42% | 14.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.16% | 26.04% | 23.81% | 1.42% | 14.36% |
| Cost of Revenue | 20.79% | 10.84% | 15.03% | 10.84% | 6.35% |
| Gross Profit | -479.17% | 53.48% | 39.06% | -113.27% | 65.17% |
| SG&A Expenses | -8.53% | -4.37% | 7.98% | 20.11% | 13.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.23% | 2.35% | 11.11% | 15.81% | 10.14% |
| Operating Income | -3.56% | 10.82% | -3.28% | -26.45% | -7.27% |
| Income Before Tax | -88.01% | 97.87% | -10.21% | -141.73% | -303.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.01% | 97.87% | -10.21% | -141.73% | -303.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.01% | 97.87% | -10.21% | -141.73% | -303.69% |
| EBIT | -3.56% | 10.82% | -3.28% | -26.45% | -7.27% |
| EBITDA | -1.18% | 12.89% | -2.86% | -27.73% | -7.96% |
| EPS Basic | -71.51% | 97.93% | -8.38% | -139.78% | -301.19% |
| Normalized Basic EPS | -71.53% | 41.04% | -8.38% | -139.86% | -301.59% |
| EPS Diluted | -46.10% | 19.38% | -7.24% | -75.93% | -4.92% |
| Normalized Diluted EPS | -84.40% | 45.01% | -16.54% | -157.79% | -301.71% |
| Average Basic Shares Outstanding | 9.63% | 3.11% | 1.67% | 0.83% | 0.51% |
| Average Diluted Shares Outstanding | 1.99% | 10.61% | -5.44% | -6.22% | 0.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |